Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...
Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for ...
KUALA LUMPUR: BMS Holdings Bhd made a lacklustre debut on the ACE Market of Bursa Malaysia today, opening below its initial public offering (IPO) price of 22 sen per share. The Johor-based building ...
Abstract: Pollution and fossil fuels are being strongly concerned. Electric vehicles were developed to solve a part of this problem. The source of energy used for electric vehicles is electricity, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback